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Abstract
The liver has the unique capacity to regenerate in response to a damaging event. Liver
regeneration is hereby largely driven by hepatocyte proliferation, which in turn relies on cell
cycling. The hepatocyte cell cycle is a complex process that is tightly regulated by several well-
established mechanisms. In vitro, isolated hepatocytes do not longer retain this proliferative
capacity. However, in vitro cell growth can be boosted by immortalization of hepatocytes. Well-
defined immortalization genes can be artificially overexpressed in hepatocytes or the cells can be
conditionally immortalized leading to controlled cell proliferation. This paper discusses the
current immortalization techniques and provides a state-of-the-art overview of the actually
available immortalized hepatocyte-derived cell lines and their applications.
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1. Introduction
In the field of hepatology, when orthotopic liver transplantation is not possible, human
primary hepatocytes represent the ‘gold standard’, in particular for the establishment of
bioartificial liver (BAL) support systems [1, 2]. They also serve as an important tool in
research and are of particular interest for in vitro pharmaco-toxicology [3, 4]. Consequently,
there is a considerable and increasing demand for human primary hepatocytes, yet their use
is hampered by inadequate supply, high cost, high variability and low in vitro proliferation
capacity. These constraints have prompted a large-scale search for alternative cell sources,
such as hepatic cell lines and stem-cell derived hepatocytes [2, 5-9]. In contrast to primary
cells, cell lines are readily available, and usually have an unlimited growth potential and
high reproducibility [10, 11]. Hepatic cell lines are either derived directly from liver tumor
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tissue or artificially generated from primary hepatocytes in vitro [5, 6].Several hepatoma-
derived cell lines preserve some liver-specific functions, but most of them, with exception of
the HepaRG® cells, do not exhibit sufficient functionality to be of pharmaco-toxicological
relevance [12-18]. Immortalized hepatocytes are typically derived from healthy primary
hepatocytes by using a defined immortalization strategy. Both fetal and adult hepatocytes
from different species have already been successfully immortalized, whether or not using a
combination of viral oncogenes and the human telomerase reverse transcriptase (hTERT)
protein [7, 9, 19-25]. The purpose of this paper is to discuss the different current
immortalization strategies and provide an overview of the actually available immortalized
hepatic cell lines and their applications. To fully understand these immortalization
techniques, the processes of hepatocyte proliferation and senescence are briefly outlined in
the preceding part.
2. Hepatocyte proliferation
2.1. Priming phase and commitment to hepatocyte cell cycle progression
Under normal conditions, the adult liver has very little proliferative activity. However, upon
partial removal of liver tissue, the remaining intact hepatic lobes start to grow and liver mass
is restored within seven to ten days due to the proliferation of mature hepatocytes [26, 27].
Multiple genes involved in cytokine networks become differentially expressed and regulate
the initiation of this liver regeneration, a process called the “priming phase” [28-30]. During
this step, G0/G1 cell cycle transition and early G1 progression are accomplished and
hepatocytes become responsive to mitogenic signals, which leads to deoxyribonucleic acid
(DNA) replication [28, 30, 31]. During collagenase perfusion of the liver, a critical step in
the isolation procedure of hepatocytes, the messenger ribonucleic acid (mRNA) levels of the
proto-oncogenes c-jun and c-fos rapidly increase, suggesting that enzymatic liver
dissociation triggers the G0/G1 cell cycle transition of hepatocytes [32, 33]. Indeed,
collagenase perfusion of the liver, which is accompanied by release of the cytokine tumor
necrosis factor α as well as activation of the intracellular nuclear factor kappa-light-chain-
enhancer of activated B cells and mitogen-activated protein kinase (MAPK) pathways, can
induce priming of quiescent hepatocytes [28, 32, 34-36]. When the freshly isolated
hepatocytes are plated, the sequentially increased expression of other proto-oncogenes, such
as junB, junD, c-myc, p53 and c-Ki-ras, indicates that the hepatocytes can proceed to the
mid-late G1 phase [28, 32]. However, further progression towards the G1/S cell cycle
boundary is only possible after stimulation with appropriate growth factors to overcome the
mitogen-dependent mid-late G1 restriction point [32]. This major checkpoint is regulated by
the tumor suppressor retinoblastoma protein (pRB) and controls whether the cellular
environment supports proliferation [37-39]. The need for mitogenic signals to pursue cell
cycling has also been shown in vivo, though intrinsic differences exist between the in vivo
and in vitro conditions [31, 40]. In vivo, normal adult hepatocytes return to the G0 state in
the absence of growth factor stimulation, but that is not the case in vitro [26, 36, 40]. After
attaching to the culture dish, surviving cells remain at the mid-late G1 restriction point, do
not proliferate and die early [36, 41].
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Several studies designated cyclin D1 as the major intracellular mediator of the mitogenic
signals responsible for the regulation of hepatocyte proliferation [32, 40, 42-45]. As such,
overexpression of D-type cyclins seems sufficient to overcome the mid-late G1 restriction
point and triggers hepatocyte proliferation both, in vivo and in vitro, in the absence of
mitogens [43, 45, 46]. Though the latter has been challenged by Wierod et al. [47].
Interestingly, fetal hepatocytes, which express both cyclin D2 and D3, possess a high
proliferation rate that is, at least partly, independent of mitogenic pathways and
characterized by the constitutive phosphorylation of pRB [48, 49].
Critical growth factors involved in hepatocyte cell cycling include hepatocyte growth factor
(HGF), epidermal growth factor (EGF), transforming growth factor (TGF) α, heparin-
binding EGF-like growth factor and amphiregulin [29, 50]. Once passed the mid-late G1
restriction point, hepatocytes are irreversibly committed to replicate and no longer require
growth factors to complete the first cycle of cell proliferation [40]. From this point onwards,
progression through the cell cycle proceeds autonomously and is driven by the sequential
formation, activation and destruction of a series of structurally related serine/threonine
protein kinase complexes, each composed of a regulatory and a catalytic subunit, cyclin and
cyclin-dependent kinase (cdk), respectively [28, 42].
2.2. Hepatocyte cell cycle regulation and control
To date, at least 20 different cdk proteins and 30 cyclins have been identified in mammalian
cells. However, only some are involved in cell cycle regulation [28, 51, 52]. Whereas the
cdks are expressed throughout the hepatocyte cell cycle, with the notable exception of cdk1,
most cyclins display a temporal expression profile, leading to periodic activation of their
respective cdk counterparts [36, 42, 53]. Since these individual cyclin/cdk complexes
perform unique functions in the cell cycle, their sequential assembly and activation dictates
the order in which the cell cycle events occur [28, 51, 54, 55] (Fig.1.). Nevertheless,
subsequent progression through the S, G2 and M phases can be impeded by additional cell
cycle checkpoints, which are switched on in response to unfavorable conditions [42]. In this
context, checkpoints at the G1/S and G2/M boundaries ensure the orderly unfolding of
different cell cycle events and inhibit cell cycling in response to DNA damage. Overall,
mechanisms associated with activation of the p53/p21 pathway and suppression of the cdc25
family phosphatase activity are initiated, which results in reduced cdk activity and cell cycle
arrest [38, 42, 55]. Indeed, in addition to cyclin binding, cdk activity is also regulated by a
critical phosphorylation/dephosphorylation equilibrium and counteracted by cell cycle
inhibitory proteins, called the cdk inhibitors (cdki) [42, 51, 55] (Fig.1.). Based on their
structure and the identity of the cdk targets, two families of cdki have been described,
namely the Ink4 family and the Cip/Kip family. The former comprises four distinct proteins,
namely p15, p16, p18 and p19/p14, which are specific inhibitors of cdk4/6. The Cip/Kip
family proteins, including p21, p27 and p57, bind and inhibit different cdk/cyclin complexes
[42, 55].
3. Hepatocyte senescence
Following partial hepatectomy (PH), the remaining hepatocyte population needs to divide on
average 1,6 times before the normal liver mass is restored and the regeneration is put back
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on hold [26, 31, 56]. It has been suggested that TGFβ and activin A, known inhibitors of
hepatocyte mitosis, as well as extracellular matrix-driven signals, underlie the termination of
hepatocyte growth when the liver regeneration is completed [57-59]. During chronic liver
injury, human hepatocytes are repeatedly stimulated to proliferate due to iterative waves of
liver destruction and regeneration [60]. This in vivo proliferation capacity was further
highlighted by the efficient repopulation of Fah−/−/Rag2−/−/Il2rg−/− mice with human adult
hepatocytes for at least four sequential rounds [61]. However, human hepatocytes cannot
proliferate indefinitely. Liver cirrhosis is accompanied by a significant rate of hepatocellular
senescence and characterized by considerable short hepatocyte telomeres [60]. In humans,
telomerase activity of most cell types is repressed early during development. Consequently,
telomere DNA in proliferating somatic cells undergoes progressive attrition. Once a critical
minimal length is reached, cellular growth is arrested irreversibly, a process known as
replicative senescence, which was first described by Hayflick and Moorhead nearly 50 years
ago [2, 62-64]. One way to overcome telomere-dependent senescence is by reactivating the
telomerase activity with exogenous hTERT [65-67]. In contrast to humans, rodents display
substantial telomerase activity in several somatic tissues, including the liver [62, 68-71].
Their telomerase activity increases 24 hours after PH and is enhanced by the preoperative
treatment with EGF and HGF, but repressed by MAPK kinase inhibitors [72]. In primary
rodent hepatocyte cultures, upregulation of telomerase activity was only notable or further
enhanced after addition of growth factors to the culture medium [70, 72]. The high
regeneration capacity, characteristic of rodent livers, may be linked to this strong telomerase
activity [71]. In this regard, serially transplanted adult mouse hepatocytes have been
demonstrated to divide as many as 69 times [31, 73].
However, in vitro, both human and rat adult hepatocytes do not possess spontaneous cell
growth and their proliferation capacity remains usually quite limited even when cultured
under growth promoting conditions [31, 68, 74-76]. The in vitro premature growth arrest,
observed in primary hepatocyte cultures could be related to a telomere-independent
senescence mechanism, which remains to be fully elucidated, but is suggested to involve
tumor suppressor proteins and cdki [63, 77]. Indeed, several studies support the contribution
of cdki p21 and/or p16 to the inhibition of DNA synthesis in primary hepatocyte cultures
[78-82]. In this respect, it was demonstrated that the second cell cycle G1 block caused by
chronic MAPK pathway activation in mitogen stimulated primary hepatocyte cultures is
partly related to p21 induction. Of note, transient MAPK pathway inhibition allows the
establishment of multiple replication rounds in these hepatocyte cultures [79].
4. Hepatocyte immortalization strategies
Immortalized hepatocytes are defined as a population of indefinitely dividing parenchymal
cells that retain critical liver functions [68]. Since mature hepatocytes normally possess only
limited growth potential when stimulated in vitro, immortalization strategies have been
developed based mainly on the transduction or transfection of hepatocytes with well-known
immortalizing genes. The most frequently used immortalization methods are (i)
overexpression of viral oncogenes, (ii) forced expression of hTERT, or (iii) a combination of
both [9, 68]. Moreover, some other immortalization genes as well as conditional approaches
for hepatocyte immortalization have been described (Fig.2. & Table 1 & Table 2).
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4.1. Immortalization genes
Viral oncogenes—Viral oncogenes include the adenoviral E1A/E1B genes, the simian
virus 40 large T antigen (SV40 Tag) and the human papillomavirus 16 (HPV16) E6/E7
genes [68]. All of them have been used to establish hepatocyte-derived cell lines, such as
C8-B, HepLL, HHL, AdPX3/4, Fa2N4, HepLi-4 and NKNT-3, suggesting that
overexpression of viral oncogenes may be sufficient to overcome the premature in vitro
growth arrest of cultured hepatocytes [19, 25, 83-87]. These viral oncogenes typically
interfere with cell cycling by inhibiting the p16/pRB and p53 pathways [39, 68]. Hepatic
cell lines have also been developed from livers of transgenic rodents overexpressing SV40
Tag [88-90].
While the use of viral oncogenes, e.g. SV40 Tag, has been shown to be sufficient to
immortalize rodent cells, overexpression of these oncogenes in human cells most likely only
extends lifespan. Immortalization per se requires telomerase reactivation either through
mutations or by the use of a second immortalizing gene, hTERT [2, 10, 20, 23, 68, 91, 92].
Furthermore, the use of a combined strategy involving a viral oncogene and hTERT, has
also been reported to produce more genetically stable cells [11, 67, 68, 93, 94]. Indeed
single use of viral oncogenes has often been demonstrated to induce chromosomal
abnormalities [95-101]. Even though karyotype analysis of newly produced hepatic cell
lines has not routinely been performed, chromosomal abnormalities have been described in
different cell lines even with combined immortalization [20, 21, 102-104]. It is important to
mention, however, that activation of an additional oncogene, such as ras is usually needed to
observe tumorigenicity [84, 105-107].
Human telomerase reverse transcriptase—The single use of hTERT for
immortalization has been suggested to avoid some of the genetic and phenotypic instabilities
related to the use of oncogenes and is limited to a number of human cell types, including
fetal and neonatal hepatocytes [2, 6, 7, 9, 10, 108, 109]. Unlike adult hepatocytes, these
immature cells can still proliferate in vitro and hence do not need cell cycle stimulation for
immortalization [2, 6, 7, 9, 49, 109]. However, fetal and neonatal human hepatocytes do not
possess indefinite growth potential because inactivation of telomerase causes replicative
senescence. Consequently, they require overexpression of hTERT to become immortalized
[2, 7, 9, 109]. Contradicting results have been reported when only hTERT was used for
immortalization of human adult hepatocytes [20, 110, 111]. As telomerase activity probably
does not allow adult hepatocytes to overcome the proposed telomere-independent growth
arrest, overexpression of hTERT may be insufficient to drive adult hepatocytes through the
cell cycle [5, 7, 66, 68].
Miscellaneous immortalization genes—Specific combinations of immortalization
genes, such as SV40 Tag with hTERT and B lymphoma Moloney Murine Leukemia virus
(Mo-MLV) insertion region 1 homolog (Bmi-1), have been used to immortalize mature
human hepatocytes. Bmi-1, like the viral oncogene HPV16E7, is involved in the inactivation
of the p16/pRB pathway. On the other hand, simultaneous transduction with Bmi-1 and
hTERT appears insufficient to immortalize the non-dividing hepatocytes [23]. Likewise, a
combined HPV16E7/hTERT approach did not promote unlimited growth of human adult
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hepatocytes [20]. A particular cell line has been produced by co-transfection of human adult
hepatocytes with p53 and pRB antisense constructs and plasmids that include E2F and
cyclin D1 genes [112]. Furthermore, it seems that the hepatitis C core protein can also
specifically immortalize mature human hepatocytes [10, 113, 114]. This core protein is able
to induce c-myc and cyclin D1 expression in primary human hepatocytes via activation of
the signal transducer and activator of transcription 3 pathway [115].
In general, most of the generated hepatocyte-derived cell lines are not tumorigenic, but
display reduced or only limited liver-specific functionality [7, 20, 102]. Taking into account
that proliferation and differentiation are mutually exclusive in vitro, it has been shown that
overexpression of the cdki, p21 and the use of conditional immortalization strategies can
stimulate to some extent differentiation of the cells [6, 23, 84, 85, 102, 111, 116-120]. Other
anti-dedifferentiation strategies developed to counteract the loss of functionality in primary
hepatocyte cultures, including co-culture systems and overexpression of liver-specific genes
have also proven usefull [121, 122].
4.2. Conditional immortalization strategies
Conditional immortalization enables the development of growth-controlled cell lines. At
least three strategies have been reported to conditionally immortalize hepatocytes, namely
(i) temperature-based regulation, (ii) recombinase-based regulation and (iii) transcriptional
regulation. All these methods rely on the observation that hepatocyte proliferation only takes
place when immortalizing genes are expressed [10] (Fig.2. & Table 1 & Table 2).
Temperature-based regulation—This method uses a temperature-sensitive SV40 Tag
mutant. The immortalizing gene is expressed and active only at the permissive temperature
(33°C), leading to the proliferation of hepatocytes. At higher temperatures (37-39°C), the
immortalization gene is inactivated and cell cycle progression is no longer stimulated [10].
As no other temperature-labile immortalizing genes have yet been identified, this method is
confined to SV40 Tag [10]. Moreover, the use of this strategy is not accompanied by the
excision of the immortalization gene from the genome and thus could present a potential risk
of tumorigenesis [84, 106, 123]. Nevertheless, some conditionally immortalized hepatic cell
lines are based on this principle, and these cell lines can be transplanted efficiently in rat
models of acute liver failure and chronic hepatic encephalopathy, usually without
occurrence of tumorigenicity [88, 90, 102, 118-120, 124, 125]. However, concerns related to
tumorigenicity form an important restriction to clinical appreciation of immortalized human
hepatocytes [20]. Importantly, the temperature shift associated with this methodology might
induce changes in cellular properties, which can complicate the interpretation of the study
outcome. A more sophisticated system based on recombinase regulation is thought to offer a
solution for these issues [10, 88, 118, 126, 127].
Recombinase-based control—The site-specific recombinase strategy uses recombinase
expression to excise chromosomal DNA segments flanked by two recombination sequences
and thereby irreversibly reverts immortalization [10, 128]. Numerous site-specific
recombination systems, including the Cre-loxP and the FLP-FRT system, have been used to
establish reversible immortalization. These systems have different efficiencies, whereby the
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Cre-loxP system stands out [123, 128]. In this system, immortalization genes are flanked by
two identical DNA sequences, called LoxP sites. The excision of these genes is regulated by
Cre recombinase [68, 123]. Proper reversion thus depends on the efficient transfer of the
recombinase gene [10]. More recently, a new method based on tamoxifen-mediated self-
excision has been established, rendering secondary virus-mediated transfer of the
recombinase gene superfluous [87, 110, 111]. Furthermore, the suicide gene herpes simplex
virus thymidine kinase (HSV-TK) has been introduced in the recombination construct as
negative selection marker. Using this strategy, cells that still express the immortalization
gene and HSV-TK gene due to improper recombination can be eliminated by exposure to
ganciclovir [23, 123]. Reversible immortalization of numerous hepatocyte-derived cell lines,
including C8-B, NKNT-3, IHH and 16T-3 depends on this recombinase-based control
approach [23, 84, 85, 110, 111, 129, 130].
Transcriptional regulation—In this method, immortalization reversibility is obtained by
transcriptional control of immortalization gene expression and not by recombinase activity.
In this way, the risk of chromosomal rearrangement is avoided and repeated cycles of
hepatocyte proliferation and growth arrest are allowed [10, 126, 127]. Transcription of
immortalizing genes can be controlled by using an artificial promoter/transactivator system,
such as the well-known tetracycline system [10]. Two approaches are currently available,
the tet-off and the tet-on system, which are composed of a tetracycline-regulated promoter
and a tetracycline transactivator (tTA) or reverse tetracycline transactivator (rtTA),
respectively. When doxycycline is added to the cell culture medium, it binds to the
transactivator. In the tet-on systems, bound rtTA interacts with the tetracycline-regulated
promoter and induces the expression of the regulated gene. When using the tet-off method,
immortalization genes are expressed in the absence of doxycycline, since only unbound tTA
can interact with the gene promoter [126, 131]. The tet-on approach has been successfully
used to produce a fetal liver cell line [7]. A drawback of this method, however, is the leaky
transgene expression caused by undesired rtTA-tetracycline promoter binding in the absence
of doxycycline [126, 131]. A tighter regulation of the transgene expression can be obtained
by combining the rtTA system with a tetracycline-controlled transcriptional silencer [131].
4.3. Gene transfer
An effective gene transfer method is of utmost importance for immortalizing hepatocytes
[91]. Different nonviral and viral methods have been used to generate immortalized
hepatocyte-derived cell lines, namely plasmid transfection, viral transduction and the use of
human artificial chromosomes.
Plasmid transfection—Various approaches are available for transfecting plasmids into
primary hepatocytes [91, 132]. Due to immortalization, stably transfected cells are selected,
allowing simple transfection procedures to be used [132]. Examples of common transfection
methods that have been used to immortalize hepatocytes include calcium phosphate
precipitation and electroporation [24, 25, 133, 134]. However, both approaches typically
display low gene transfer efficiencies and high hepatocyte toxicity [91, 132]. Replacement
of calcium by strontium eliminates toxicity but the gene transfer efficiency remains low
[91]. Other researchers explored liposomes as gene carriers for hepatocyte immortalization
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[21, 83, 112, 135-137]. When properly optimized, lipid-mediated gene transfer can achieve
high gene transfer efficiencies compared to other transfection approaches [91]. Furthermore,
using hepatocyte-specific ligands, more hepatocyte-specific transfections can be achieved
[132].
Viral transduction—Transduction with viral particles covers a widely used methodology
for gene transfer. Among the available viral vectors, retroviral and lentiviral vectors induce
stable integration of the immortalization gene and thus generate sustained transgene
expression in the progeny [132, 138]. Furthermore, these vectors do not provoke harmful
immune responses and allow integration of large genes [139]. Retroviral vectors, such as the
Mo-MLV-derived vectors, have been frequently used to establish human and rodent hepatic
cell lines [2, 9, 19, 84, 87, 102-104, 108, 110, 111, 118, 119, 124, 140, 141]. A major flaw in
this system is its inability to transduce non-dividing cells, which makes it unsuitable for non-
proliferating cells, including hepatocytes [139, 142]. Even when growth factors are added to
the cell culture medium to induce hepatocyte mitosis, the efficiency of transduction usually
remains limited [132, 139, 142, 143]. Lentiviral vectors derived from the human
immunodeficiency virus (HIV) can tackle these issues and transduce both dividing and non-
dividing cells by using virus at a relatively high titer [139, 142-144]. Moreover, lentiviral
vectors provide high transduction efficiencies without affecting the differentiated hepatic
phenotype [139, 143, 145]. Although lentiviral vectors lack hepatocyte specificity, the use of
hepatocyte specific promoters can restrict the expression of lentiviral genes to the
parenchymal liver cells [144]. Several studies have demonstrated appropiate gene transfer
for immortalization of human adult and fetal hepatocytes [7, 20, 23]. Rodent hepatocytes,
especially murine hepatocytes are considerably resistant to HIV vector-mediated
transduction. This resistance has been related to a block in the immediate-early phase of
infection [142]. In addition to the use of higher viral titers, cell culture medium supplied
with growth factors, namely EGF and to lesser extent HGF, was found to improve lentiviral
transduction efficacy of primary mouse hepatocytes [142, 146]. Similarly, when transducing
human adult and fetal hepatocytes, the use of growth factors markedly upregulated the
expression of lentiviral genes. Consequently, this transduction approach offers the
possibility to reduce the viral load, which as such lowers cost and reduces cellular toxicity
[144]. Also the antioxidant, vitamin E proved to significantly enhance lentiviral transduction
rates of human and rat adult hepatocytes [142].
Human artificial chromosomes—The generation of a particular rat hepatic cell line was
made possible by a more recent gene transfer method, namely generation of human artificial
chromosome (HAC) [129, 147]. Although this method generally has lower transfer
efficiency than the use of viral vectors, the HACs possess many properties of the ideal gene
delivery vector. These include mitotically stable episomal maintenance and incorporation of
large genes under control of their regulatory elements, allowing a correct, physiological
regulated transgene expression. Furthermore, due to their episomal nature, integration-
related complications, such as oncogenesis, should be avoided [138]. Immortalization of
human fibroblasts using HAC-mediated episomal expression of hTERT has also been
described, potentially offering new perspectives for hepatocyte immortalization [148].
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5. Application of immortalized hepatic cell lines
It has repeatedly been postulated that immortalized hepatic cell lines which may offer an
unlimited supply of well-characterized, pathogen-free cells could represent an attractive
alternative for primary hepatocytes in several clinical applications as well as fundamental
and applied research [106, 147, 149]. So far, multiple studies based on immortalized
hepatocytes have already been performed.
5.1. Clinical application
Hepatocyte transplantation—The use of different animal models of hepatic impairment
made it possible to demonstrate the therapeutic efficiency of transplanted cell lines. In this
regard, it was shown that transplantation of conditional immortalized rat hepatocytes could
protect portacaval-shunted rats from hyperammonia-induced hepatic encephalopathy [119,
149], improve survival of rat with acute liver failure (ALF) [125], adjust for bilirubin
conjugation defect in Gunn rats [150, 151] and correct the global hepatic abnormalities
associated with end-stage liver failure in cirrhotic animals [149]. Likewise, several human
adult and fetal hepatic cell lines, including HHE6E7T1, NKNT-3, IHH, HepCL, 16T-3 and
OUMS-29 were confirmed to promote survival in a pig [111], rat [152] or mice [23, 124,
153] model of ALF. Furthermore, YOCK-13, an insulin-producing human hepatic cell line
was reported to control diabetes when transplanted into totally pancreatectomized diabetic
pigs [110].
Bioartificial liver systems—For large-scale applications that rely on in vitro hepatic
functionality, such as BAL systems, the development of a hepatic cell line that combines
both in vitro hepatic function and proliferation capacity would be of great value.
Two human fetal hepatic cell lines, namely HepLi-4 and cBAL111, have already been
evaluated as a potential cell source for BAL systems [87, 154]. However, it was revealed
that both cell lines possessed insufficient hepatic functionality to be applicable for in vitro
applications. The need for in vitro culture conditions that mimic the in vivo situation and
promote hepatocyte differentiation in vitro was clearly emphasized [7, 87, 154]. This was
further supported by experiments, which showed that cBAL111 cells are able to partly
differentiate into functional hepatocytes once transplanted in vivo [7].
Different human adult hepatic cell lines have also been proposed as possible candidates for
BAL application, but as for the modified fetal hepatic cell line, OUMS-29/H-11, data on
efficacy in animal models of severe liver failure are currently lacking [112, 141, 155-158].
However, the production of ammonia [155] or possible inability to eliminate ammonia [141]
are undesirable features for a BAL [158].
Another modified adult hepatic cell line composed of TTNT cells overexpressing IL-1 Ra
has already been tested and was not able to improve survival of an ALF rat model [158].
5.2. Fundamental and applied research
Nowadays, human and rodent hepatic cell lines, such as CWSV [159, 160], H2.35 [161,
162], NeHepLxHT [163], OUMS-29 [164] and THLE [165, 166] are still being used for
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fundamental research. In this regard, a lot of investigations related to hepatotropic viruses
have been performed on TPH1 cells [167, 168]. Furthermore, a murine model of HBV
viremia based on immortalized human hepatocytes transfected with hepatitis B virus DNA
has been created and offers the opportunity for in vivo HBV studies [169]. Several hepatic
cell lines have also proven useful as in vitro tool for screening and safety testing of drug
candidates. For instance, Hc3716-hTERT cells represented the first model for predicting the
side-effects of telomere-targeting drugs in normal cells and it was suggested that the Fa2N4
cell line could be used for routine screening during discovery for pregnane X receptor
mediated CYP3A4 induction [108, 170].
6. Conclusions and perspectives
In vitro expansion of human hepatocytes has gained considerable attention, as it might serve
many clinical applications and fundamental research purposes. Prominent examples include
the establishment of a bioartificial human liver device that can be used to bridge the time
until liver transplantation is possible and the creation of a liver-based in vitro tool for
screening and safety testing of drug candidates. As freshly isolated and cultured mature
hepatocytes inherently have very poor growth potential, efforts have been focused on
strategies to immortalize primary hepatocytes while maintaining their liver-specific
functions. The currently available methods include transduction or transfection with
prototypical immortalization genes and conditional immortalization by temperature-based
regulation, recombinase-based control and transcriptional regulation. Although hepatocyte
immortalization has been explored for years, it is still in its infancy since no cell lines with
high hepatic functionality are yet available. As already postulated more attention should be
paid to culture systems that support differentiation of the immortalized hepatocytes [6, 7,
87]. The past decade witnessed the introduction of novel strategies for cell immortalization
based on the use of cell cycle regulators to surmount the p16-regulated premature growth
arrest observed in several epithelial cells [171, 172]. Similarly, human myogenic cells
immortalized by combined overexpression of hTERT, cyclin D1 and a mutant cdk4 isoform
were able to overcome a p16-regulated precocious growth arrest without loss of their
differentiation potential [173]. Although direct sequestration of p16 could not induce
hepatocyte proliferation, it is worthwhile to examine the blocking of p16 control and pRB
activity by overexpression of cell cycle regulators [20, 23]. A prerequisite to develop novel
hepatocyte immortalization strategies is further fundamental research on the regulation of
liver cell growth, especially in vitro. Such efforts should be strongly encouraged as they
could lead to the generation of a robust hepatocyte-derived cell line with sustained liver-
specific functionality resembling the in vivo situation. It can be anticipated that such a
system will not only trigger a lot of interest among clinicians but also in the area of in vitro
pharmaco-toxicology.
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BAL bioartificial liver
(h)TERT (human) telomerase reverse transcriptase
G gap
DNA deoxyribonucleic acid
mRNA messenger ribonucleic acid
MAPK mitogen-activated protein kinase
pRB retinoblastoma protein
HGF hepatocyte growth factor
EGF epidermal growth factor
TGF transforming growth factor
cdk(s) cyclin-dependent kinase(s)
S synthesis
M mitosis
cdki cdk inhibitor
PH partial hepatectomy
SV40 Tag simian virus 40 large T antigen
HPV16 human papillomavirus type 16
Mo-MLV Moloney Murine Leukemia virus
Bmi-1 B lymphoma Mo-MLV insertion region 1 homolog
HSV-TK herpes simplex virus thymidine kinase
tTA tetracycline transactivator
rtTA reverse tetracycline transactivator
HIV human immunodeficiency virus
HAC human artificial chromosome
ALF acute liver failure
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Key Point Box: Hepatocyte immortalization strategies
• Commonly used immortalization genes include viral oncogenes and hTERT.
• Gene transfer is accomplished by viral and nonviral methods.
• Conditional immortalization enables the production of growth-controlled cell
lines.
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Fig.1. The hepatocyte cell cycle and its regulation
(A) The hepatocyte cell cycle, as in other eukaryotic cells, is composed of four phases
namely the G1, S, G2 and M phase. Under physiological conditions, most hepatocytes in the
adult liver escape the active cell cycle and enter a quiescent stage, known as the G0 phase.
In this state, hepatocytes do not proliferate, but remain metabolically active. Upon
appropriate stimulation, hepatocytes re-enter the cell cycle in the G1 phase [42, 174].
Progression through the mid-late G1 phase is growth factor-dependent. Once beyond the
mitogen-dependent restriction point (RP), the cell cycle is completed autonomously, driven
by the sequential activation of a series of structurally related serine/threonine protein
kinases, the cyclin dependent kinases (cdk) [42]. In contrast with other mammalian cells,
hepatocytes possess active cyclin A-cdk1 and cyclin B-cdk1 complexes during the S-phase
of their cell cycle, which is suggested to allow rapid and efficient hepatocyte proliferation
[175].
(B) The kinase activity of the cdks is tightly regulated by several different mechanisms,
including binding to cyclins, binding by cdk inhibitors (cdki) and various phosphorylation/
dephosphorylation events.
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For example full activation of the cyclin B- cdk1 complex requires its phosphorylation (P)
on threonine 161 by the cdk-activating kinase (CAK). Other phosphorylation/
dephosphorylation events fine tune kinase activity and thereby facilitate proper mitotic
action. Wee1 negatively affects kinase activity by phosphorylating cdk1 on threonine (T) 14
and tyrosine (Y) 15, whereas cdc25 phosphatase restores kinase activity by
dephosphorylation of the same amino acids. Furthermore, Cip/Kip cdki can bind to the
cyclin B/ckd1 complexes and inhibit their action [39, 42, 51, 55]. Adapted from [28, 51].
CAK, cdk-activating kinase; cdk(i), cyclin dependent kinase (inhibitor); G, gap; M, mitosis;
P, phosphorylated; RP, restriction point; S, synthesis; T, threonine; Y, tyrosine.
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Fig.2. Hepatocyte immortalization strategies
Several hepatocyte immortalization strategies are available, including transduction or
transfection of prototypical immortalization genes. Conditional immortalization by
temperature-based regulation, recombinase-based control and transcriptional regulation has
been introduced to establish growth-controlled cell lines. Adapted from [10].
rtTA, reverse tetracycline transactivator; TRE, tetracycline responsive element; tTA,
tetracycline transactivator.
Eva et al. Page 25
J Hepatol. Author manuscript; available in PMC 2014 October 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Eva et al. Page 26
Table 1
Overview of the functionality and immortalization strategy of in vitro established human
and rodent hepatic cell lines
A1AT, αl-antitrypsin; AFP, α-fetoprotein; AhR, aryl hydrocarbon receptor; ALB, albumin; ALF, acute liver
failure; A2M, α2-macroglobulin; APO, apolipoprotein; Arnt, AhR nuclear translocator; ASGP(R),
asialoglycoprotein (receptor); BCRP, breast cancer resistance protein; Bmi-1, B lymphoma Mo-MLV
insertion region 1 homolog; BSEP, bile salt export pump; CAR, constitutive androstane receptor; C/EBP,
Ccaat-enhancer-binding protein; CD, cluster of differentiation; CK, cytokeratin; CLDN, claudin; CYP,
cytochrome P450; DMSO, dimethyl sulphoxide; DPP, dipeptidyl peptidase; EH, epoxide hydrolase; EPCAM,
epithelial cell adhesion molecule; GGT, γ-glutamyltranspeptidase; G6P, glucose-6-phosphate; GPX,
gluthatione peroxidase; GS, glutamine synthetase; GST, gluthatione S-transferase; HBCF, human blood
coagulation factor; HGFR, hepatocyte growth factor receptor; HNF, hepatocyte nuclear factor; HPV, human
papillomavirus; hTERT, human telomerase reverse transcriptase; IL, interleukin; INF, interferon; MDR,
multidrug resistance protein; mRNA, messenger ribonucleic acid; MRP, multidrug resistance-associated
protein; NADPH, nicotinamide adenine dinucleotide phosphate; NCAM, neural cell adhesion molecule;
NTCP, sodium taurocholate cotransporting polypeptide; OATP, organic anion transporting polypeptide; OCT,
organic cation transporter; PEPCK, phosphoenolpyruvate carboxykinase; PT, prothrombin; PXR, pregnane X
receptor; Rb, retinoblastoma; SCID, severe combined immunodeficiency; SOD, superoxide dismutase; SV40
Tag, simian virus 40 large T antigen; TAT, tyrosine aminotransferase; TF, transferrin; UGT,
uridinediphosphate-glucuronosyltransferase.
Human hepatic cell lines
Cell line Immortalization strategy Functionality Ref
Fa2N-4
Adult hepatocytes - Possessed, in comparison with
cryopreserved human hepatocytes:
■ Significantly lower basal
expression level of the
nuclear receptor CAR
and several drug
metabolizing enzymes
and transporters, namely
CYP1A2/2D6/2E1/1A1,
UGT1A1/1A6/2B15/2B4,
sulfotransferase, NTCP,
OCT1, OATP1B1/1B3,
MRP2 and BSEP.
■ Markedly higher MDR1
mRNA levels.
■ Similar basal expression
of BCRP, PXR and AhR.
■ Apparently higher
expression of most
transcription factors and
coactivators/corepressors
that have been associated
with PXR and CAR
mediated enzyme
induction.
- Were incapable of metabolizing
compounds due to low basal levels of
drug-metabolizing enzymes.
- Exhibited, at early passage, inducible
CYP1A2/2C9/3A4, UGT1A and
MDR1 mRNA levels as well as
[22, 86, 176]
Transfection
SV40 Tag
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Human hepatic cell lines
Cell line Immortalization strategy Functionality Ref
CYP1A2/2C9/3A4 activities and could
distinguish inducers from non-
inducers. At higher passages, the cells
lost the ability to induce.
- Were not tumorigenic.
FH-TERT
Fetal hepatocytes - Expressed CYP450 mRNA and
maintained, in contrast to passaged
fetal hepatocytes, liver-enriched
differentiation markers, especially C/
EBPα and HNF4 as well as elevated
levels of HGFR.
- Possessed glycogen storage and G6P
activity, in a pattern similar to primary
fetal hepatocytes.
- Produced urea and retained level of
ALB synthesis equivalent to HepG2
cells.
- Displayed no in vitro anchorage-
independent growth or in vivo tumor
formation.
- 4 weeks after intrahepatic
transplantation in immunodeficient
mice, FH-hTERT engrafted, survived
and expressed ALB, A1AT, and TF
mRNA levels comparable with
primary human hepatocytes. These
experiments illustrated the ability of
FH-hTERT to differentiate into mature
hepatocytes and to display significant
hepatocellular gene expression.
➢ Culture conditions used in these
studies were designed at supporting
cell proliferation, and conditions have
not been optimized for inducing
differentiated hepatocellular functions.
[2]
Retroviral vector
hTERT
Hc3716- hTERT
Fetal hepatocytes - Maintained normal mammalian cell
morphology.
- Exhibited protein expression of ALB,
CK8 and CK18, but not AFP. ALB
levels were higher than in control,
passaged Hc3716 cells.
- Possessed inducible CYP3A4/7 mRNA
levels.
- Exhibited wild-type p53
responsiveness.
- Did not show typical oncogenic
phenotype traits.
➢ In this study, it is shown that
inappropriate culture conditions
induce senescence programming in
human cells. Adapting the culture
medium allowed the human fetal
hepatocytes to extend their lifespan
over 80 passage doublings, instead of
10 in normal culture conditions.
[108]
Retroviral vector
hTERT
HepLi5
Adult hepatocytes
- Expressed HBCF-X, GS, GST, ALB
and CYP450 mRNA. [141]Retroviral vector
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Human hepatic cell lines
Cell line Immortalization strategy Functionality Ref
SV40 Tag
- Retained ALB secretion and urea
production, though at low levels
compared to primary hepatocytes.
- Dislayed CYP1A2 activity.
- Were not tumorigenic.
- Possessed significantly enhanced
cellular functions after large-scale
culture in roller bottles.
HepLL Adult hepatocytes - Displayed morphologic characteristics
of liver parenchymal cells.
- Expressed HNF4, HBCF-X, GST-n
and ALB mRNA as well as ALB and
CYP2E1 protein but no ASGP mRNA.
- Stained positive for human hepatocyte
special antigen but negative for AFP.
- Secreted ALB and urea at levels not
significantly different from primary
cultured human hepatocytes.
- Synthesized glycogen.
- Were not tumorigenic after
transplantation into SCID mice.
- Possessed a good potential of
regeneration and active metabolic
function in recipient organs.
[83]
Lipid mediated gene transfer (lipofectamine
reagent)
SV40 Tag
HepZ
Adult hepatocytes
- When grown in bioreactor, cells were
able to secrete ALB and A2M and
possessed inducible CYP450 activity.
➢ pRB andp53 constructs under control
of ALB promoter.
[112]
Lipid mediated gene transfer (lipofectamine
reagent)
Antisense constructions for Rb and p53 +
Cotransfection of E2F transcription factors
and cyclin D1
HHE6E7T-1/2
Small hepatocytes - Displayed epithelial-like morphology.
- Retained characteristics of
differentiated hepatocytes, though
functions such as ALB secretion as
well as mRNA expression levels of
ALB, HNF4 and A1AT decreased
gradually as the passages progressed.
CK18 mRNA levels were detected
throughout the culture period and no
AFP expression was observed.
- Were positive for vimentin staining.
- Showed chromosomal instability after
long-term passage.
- Exhibited no tumorigenic properties
after transplantation in SCID mice.
- Improved survival of acetaminophen-
induced ALF mice through possible
redifferentiation in vivo. It was
suggested that once transplanted, cells
may support ammonia metabolism and
gluconeogenesis, even though cells at
latter passages did not possess
ureogenesis or gluconeogenesis.
[20, 153]
Lentiviral and retroviral vectors
HPV16 E6/E7 + hTERT
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➢ In this study, transduction of hTERT
alone could not extend the life span of
normal human adult hepatocyte.
HHL(−5/−7/−16)
Adult hepatocytes - Contained markers of hepatocyte and
biliary phenotype(CK7/8/18/19).
- Expressed CYP450 protein at levels
comparable to Huh-7 and HepG2 cells.
- Produced ALB, though at lower levels
than Huh-7 and HepG2 cells.
- Stained negative for AFP and did not
display elevated nuclear expression of
p53 protein.
- Possessed active gap junctions.
- Respond to INF- α stimulation by
upregulation of major
histocompatibility complex I and II
- Exhibited, in contrast to the Huh-7 and
HepG2 cells, increased capacity to
bind recombinant hepatitis C virus-like
particles.
[19]
Retroviral vector
HPV16 E6/E7
IHH-A5
Adult hepatocytes - Were morphologically and functionally
more similar to hepatoma cell lines
than primary hepatocytes in culture.
- Secreted different plasma proteins,
including ALB, APO-B and fibrinogen
at relatively high rates, within the
range observed for early primary
human hepatocyte cultures. Addition
of IL-6 to the culture medium resulted
in increased fibrinogen secretion and
decreased ALB production,
demonstrating a proper acute-phase
response.
- Produced detectable amounts of APO-
A1.
- Exhibited bile-canalicular structures
that, in some cases, accumulated the
organic anion glutathione-
methylfluorescein. Cell cultures were
partly polarized and expressed the
efflux transporters, MDR1 and MRP1,
on the membranes of apical vacuoles
or on the lateral membranes of
adjacent, proliferating cells,
respectively.
- Did not maintain active Na+ -
dependent bile salt uptake.
- Displayed similar lipoprotein
metabolism as HepG2 cells.
[135]
Lipid mediated gene transfer (lipofectin
reagent)
SV40 Tag
NeHepLxHT
Neonatal hepatocytes - Displayed characteristic morphology
of primary fetal liver cells.
- Maintained epithelial characteristics as
evidenced by immunostaining for
epithelial cell markers, the
cytokeratins.
- Possessed gene expression profile
similar to human neonatal hepatocytes,
[9]
Retroviral vector
hTERT
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with positive expression of A1AT,
CKIT, CLDN3, EPCAM, NCAM
mRNA and no detection of AFP,
ASGPR or CYP3A4. The very low
ALB mRNA levels compared to
HepG2 cells and the expression of
CK19 in early passages, indicated the
progenitor nature of the cells.
- Retained a normal diploid karyotype.
OUMS-29
Fetal hepatocytes - Displayed epithelial morphology.
- Maintained gene expression of ALB,
ASGPR, bil-UGT, GS, GST-Π,
HBCF-X, AhR and Amt.
- Secreted ALB, AFP, TF, A1AT and
APO A-1.
- Possessed inducible CYP1A1/2 mRNA
levels and activity.
- Displayed chromosomal abnormalities.
- Protected 90% hepatectomized rats
from hyperammonemia and prolonged
their survival after intrasplenic
transplantation.
➢ Overexpression of HNF4α2 led to
development of OUMS-29/H-H cell
line with increased liver-specific gene
expression, such as A1AT,
apolipoproteins, HBCF-X and HNF1
α.
[21, 122, 136]
Lipid mediated gene transfer (lipofectin
reagent)
SV40 Tag
PH5CH
Adult hepatocytes - Displayed epithelial appearance.
- Expressed human CK and ALB
protein.
- Possessed low colony-forming
efficiency.
- Were not tumorigenic.
[137]
Lipid mediated gene transfer (lipofectin
reagent)
SV40 Tag
THLE-2/-3
Adult hepatocytes - Displayed epithelial morphology.
- Secreted ALB and expressed CK18,
TF, A1AT, A2M, GST-Π and very low
levels of GGT at early passages. CK19
expression could only be determined at
later passages. Cells were uniformly
negative for AFP and factor VIII. The
appearance of CK19 and decreased
ALB secretion at later passages
demonstrated that cells undergo
dedifferentiation in culture.
- Retained mRNA expression of phase II
enzymes such as EH, catalase, GPX,
SOD and GSTs at levels comparable to
human liver, with GST-Π and α
mRNA as the dominant form in THLE
cells or human liver, respectively.
- Maintained NADPH CYP reductase
expression at a lower steady-state
mRNA level than in human liver.
- Were able to metabolize three
carcinogens, which suggested the
[104]
Retroviral vector
SV40 Tag
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presence and activity of CYP1A2/1A1,
CYP2E1 and CYP3A4. However
CYP1A2, CYP2E1, CYP3A4,
CYP2A3 and CYP2D6 mRNA were
not detected. The steady-state mRNA
levels of CYP1A1 increased after
exposure to Aroclor 1254 or B[ α ] P.
- Displayed chromosomal abnormalities.
- Possessed no tumorigenic properties.
➢ Besides the use of viral vectors,
strontium phosphate transfection was
also applied (THLE-1 cells).
Immortalization could only be
reproducibly established by retroviral
transduction.
TPH1
Adult hepatocytes - Exhibited altered cell morphology
resembling low-differentiated
epithelial cells.
- Expressed no A1AT or AFP mRNA.
- Secreted ALB.
- Possessed G6P activity.
- Reactivated telomerase immediately
after senescence.
- Displayed anchorage-independent
growth at latter stages, providing
evidence for transformed phenotype.
[113]
Strontium phosphate precipitation
HCV core gene
Conditional immortalization
16T-3
Adult hepatocytes Reverted 16T-3 cells:
- Showed enhanced mRNA levels of
transcriptional factors, C/EBP α and
HNF4 α as well as increased mRNA
expression of hepatocyte-specific
genes, including ALB, GST-Π, HBCF-
X, bil-UGT, CYP3A4, GS and
ASGPR.
- Possessed increased ALB production
and lidocaine metabolism, though at
lower levels than normal human
hepatocytes.
- Intraportal transplantation in a pig
model of ALF induced by D-
galactosamine recovered TBL, AST,
NH and PT levels and prolonged
survival without tumor formation.
[111]
Retroviral vector
hTERT
Tamoxifen-mediated selfexcision (Cre-LoxP)
cBAL111
Fetal hepatocytes - Expressed relatively high mRNA
levels of immature markers, GST-Π
and AFP, and very low mRNA levels
of mature markers, ALB, A1AT and
TF. Transcript levels of HNF4 α
increased after prolonged culturing.
- Stained positive for GS, ALB, CK18,
CK19, vimentin and the progenitor cell
marker CD146 but displayed CK18 in
a pattern characteristic of
dedifferentiated human hepatocytes.
[7]
Lentiviral vector
hTERT
Transcriptional regulation (Tet-on approach)
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- Produced urea and ALB, though at
lower levels than mature human
hepatocytes.
- Retained no CYP1A2 & 3A4 activity
(no elimination of lidocaine) but were
able to eliminate galactose.
- Displayed no anchorage-independent
growth.
- Possessed the ability to differentiate
into functional hepatocytes once
transplanted in vivo, without the
occurrence of tumor formation.
➢ cBALUl cells resembled cells with
progenitor characteristics rather than
fully differentiated hepatocytes.
However, there was a trend of
increased and decreased expression of
mature and immature markers,
respectively, with culture time.
HepCL
Fetal hepatocytes - Displayed morphological
characteristics of liver parenchymal
cells.
- Stained positive for ALB, CK18 and
CK19.
- Produced amounts of ALB and urea
comparable to those of unmodified
primary human fetal hepatocytes.
- Were not tumorigenic after
transplantation into SCID mice.
- Transplanted cells rescued mice after
90% hepatectomy, produced ALB and
CK18 and were superior to HepG2
cells regarding metabolic support
during ALF.
[124]
Retroviral vector
SV40 Tag
Temperature-based regulation
HepLi-4
Adult hepatocytes Reverted HepLi-4 cells:
- Expressed similar GS and somewhat
lower UGT1A1 mRNA levels than
adult human liver. ALB and GST-Π
mRNA levels were extremely lower or
higher, respectively, compared to the
human liver. This indicates that
HepLi-4 cells are not fully
differentiated after reversion.
- Prolonged the survival of common bile
duct ligated mice after intrasplenic
transplantation.
- Were not tumorigenic.
[87]
Retroviral vector
SV40 Tag
Tamoxifen-mediated selfexcision (Cre-LoxP)
HLTC-7/-11/-15/-17/-19
Adult hepatocytes - Grew as islands or sheets of cuboidal
cells (HLTC-17) or displayed a more
dispersed cuboidal-elongated
morphology (HLTC-7/-11/-15/-19).
- Secreted fibrinogen at fairly constant
rate in all tested cell lines at permissive
(33,5°C) and non-permissive (39,5°C)
temperature.
[103]
Retroviral vector
SV40 Tag
Temperature-based regulation
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- Exhibited no ALB, AFP, A1AGP or
PT secretion in any cell line at both
temperatures.
- Cell lines HLTC-7,-15 and -19,
produced A1AT at permissive
temperature. However, at non-
permissive temperature the secretion of
A1AT was upregulated or became
detectable in all the cell lines.
- Cell lines HLTC-17 and -11 possessed
no CYP activity at any temperature
even after induction and stained
positive for ALB, CK18, CK7, CK19
and vimentin, but negative for CK8,
with almost identical patterns at both
temperatures.
- HLTC-17 cells showed considerable
aneuploidy with chromosomal
rearrangements. All HLTC cells
contained a derivative chromosome
with loss of the short arms of
chromosomes 11 and 12.
- Displayed no anchorage-independent
growth.
➢ The results indicated progressive
phenotypic instability and loss of
differentiated functions. Conversion to
the non-permissive temperature did
only allow significant expression of a
limited repertoire of differentiated
functions by the immortalized human
hepatocytes.
IHH10(.3)/12
Adult hepatocytes - Displayed morphology reminiscent of
differentiated hepatocytes.
- Expressed ALB, A1AT, ASGPR and
CYP450 mRNA levels.
- Secreted liver-specific proteins, ALB
and fibrinogen, at levels similar to
Huh-7 cells but lower than primary
hepatocytes. The IHH12 cell line did
only produce fibrinogen after de-
immortalization, suggesting the
acquirement of a higher differentiation
status in this setting. However, Cre-
recombinase treatment of IHH12 cells
did not significantly improve the
production of ALB.
- Possessed inducible CYP1A1/2
activity.
- Were not tumorigenic and rescued
mice from lethal doses of
acetaminophen.
➢ Combination of immortalizing genes
hTERT & Bmi-1 was insufficient to
immortalize non-dividing human
hepatocytes.
[23]
Lentiviral vector
SV40 Tag + hTERT (IHH10)
or
SV40 Tag + hTERT + Bmi-1 (IHH12)
Recombinase- based control (Cre-LoxP)
NKNT-3
Adult hepatocytes
- Displayed morphological
characteristics of liver parenchymal
cells and looked more differentiated
after reversion.
[6, 85, 136,
140, 152]Retroviral vector
SV40 Tag
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Recombinase- based control (Cre-loxP)
- Expressed bil-UGT, GS and GST-Π
mRNA levels, which increased
substantially after reversion.
Contradicting results were published
regarding expression of ALB and
HBCF-X mRNA levels. One paper
demonstrated that ALB and HBCF-X
mRNA were newly introduced in the
reverted cells whereas several other
papers already reported expression of
these genes and ASGPR mRNA in
non-reverted cells. Nevertheless,
although reversion did stimulate
differentiation, mRNA levels of ALB,
A1AT and TF were maximally 0,1% of
primary human hepatocytes.
- Were not tumorigenic after
transplantation into SCID mice and
both NKNT-3 and reverted NKNT-3
significantly improved biochemical
parameters in transplanted rats,
protecting as such 90%
hepatectomized rats from
hyperammonemia and prolonged their
survival.
➢ Additional experiments revealed that
introduction of p21 into human
immortalized hepatocytes can increase
ALB expression and induce a
differentiated morphology.
YOCK-13
Adult hepatocytes - Displayed morphological
characteristics of normal human
hepatocytes.
- Expressed markers of hepatocytic
differentiation including ALB,
ASGPR, bil-UGT, CYP3A4, GS,
GST-Π, and HBCF-X.
- Immortalized and reverted cells
possessed no tumorigenic properties in
SCID mice.
- Xenotransplantation in totally
pancreatectomized pigs, decreased
hyperglycemia and prolonged survival
without adverse effects such as portal
thrombosis, liver necrosis, pulmonary
embolism and tumor development.
➢ The YOCK-13 hepaticcell line is
derived from the reversible
immortalized human hepatic cell line,
TTNT-16-3, by co-expression of
modified insulin.
[110]
Retroviral vector
hTERT
Tamoxifen-mediated self-excision (Cre-LoxP)
Rodent hepatic cell lines
Cell line Immortalization strategy Functionality Ref
AdPX3/4
Rat adult hepatocytes - Secreted ALB at early passage, though
at lower levels than primary cultured
hepatocytes and many CWSV cell
lines. Moreover, ALB amounts
declined with continued passage in
culture. The cells also produced
additional plasma proteins, including
TF, hemopexin and C3 complement
but no AFP.
[25]
Calcium phosphate precipitation
E1A & E1B
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- AdPX4 cells were, at least at low
passage, not tumorigenic.
➢ Use of E1A or E1B gene expression
alone was insufficient to induce
hepatocyte proliferation.
➢ Transformation frequencies were
enhanced when growth factors were
added to the culture medium.
C3-II-B-2-3 C4-1-B-2
C8-IV P9 SV40RH1
Rat adult hepatocytes - Produced ALB (SV40RH1/C3-II-
B-2-3/C4-1-B-2/C8-IV).
- Possessed bil-UGT activity
(SV40RH1/P9).
- Were able to resynthesize gluthatione
from methionine and cysteine
(SV40RH1/P9).
- Expressed low levels of phase II
enzymes, GGT and GST-Π
(SV40RH1/P9).
- Contained cells expressing vimentin.
The SV40RH1 was the only cell line in
which vimentin-negative cells were
present.
[133]
Calcium phosphate precipitation
SV40 DNA
CWSV
Rat adult hepatocytes - Were derived from colonies of ALB-
producing epithelial cells, which were
morphologically more similar to
established hepatoma cell lines than
cultured primary hepatocytes.
- At low passage, the cell lines, CWSV1,
2, 14, 16 and 17 expressed high ALB
mRNA levels and possessed TF,
A1AT and PEPCK mRNA levels
which were similar to the liver but
higher than to 2 hepatoma cell lines
(H4IIEC3 & McA-RH7777). At higher
passage ALB expression decreased
only slightly in the CWSV1, 2 and 17
cell lines but markedly in CWSV14
and 16 cells. TF levels were marginally
diminished in all cell lines whereas
A1AT and PEPCK were only highly
maintained in CWSV1 and 14 cells,
respectively. No AFP expression could
be detected throughout cultivation,
except in high passaged CWSV14
cells.
- Exhibited variable ALB production,
ranging from high (CWSV1, 2, 9, 10,
14, 15, 16 and 17) to low (CWSV4 and
5) levels. CWSV8 cells did not
produce detectable ALB amounts from
passage 11 onwards. ALB-producing
cell lines also secreted other plasma
proteins, including, TF, hemopexin and
C3, but no detectable amounts of AFP.
- CWSV1, 2, 16 cells were only
tumorigenic at higher passages
whereas transplanted CWSV 14 and 17
cells already formed tumors at low
passages.
[105, 134, 177]
Calcium phosphate precipitation
SV40 DNA
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➢ Transformation frequencies were
enhanced when growth factors were
added to the culture medium.
➢ It was shown that culture conditions
used for transformation could greatly
influence the differentiated hepatic
phenotype of transformed cells. For
example formation of ALB secreting
colonies was greatly increased after
addition of DMSO to the culture
medium.
➢ Experiments demonstrated that ALB
expression was apparently
temperature-independent.
RH(1-4/6-10)
Rat adult hepatocytes - Displayed morphology consistent with
that of immature hepatocytes and
identical to certain cultured
undifferentiated hepatoma cells.
- Did not express CK19 protein levels.
- Retained ALB-positive cells, but
mRNA and protein expression were
weaker than in rat hepatocytes.
- Showed AFP protein expression in
some cell strains (RH8/9/10), but to a
lesser extent than HepG2 cells. The
functional status of these RH cells was
thought to resemble that of 10- to 17-
day-old fetal rat hepatocytes.
➢ Establishment of unique method to
specifically immortalize ALB-
expressing cells. Cultures were
cotransfected with puromycin
resistance gene under control of ALB
enhancer/promoter. Only cells derived
from hepatocytes were obtained after
drug selection.
[24]
Electroporation
SV40 Tag
SVHepB4
Rat adult hepatocytes - Displayed a hepatocyte-like
morphology.
- Maintained significant activity and
inducibility of phase I and phase II
enzymes.
- Showed low activity of GGT, a
hepatocyte dedifferentiation or
transformation marker, whereas the
hepatospecific enzyme TAT was
expressed at levels similar to those in
liver.
- Possessed no anchorage-independent
growth.
[178]
Wild type simian virus strain LP
SV40 Tag
Conditional immortalization
Rat adult hepatocytes - Immortalized cells cultured at
permissive temperature (33°C)
expressed low mRNA and protein
levels of ALB, ASGPR and
androsterone-UGT but high mRNA
and protein levels of GST-Yp,
compared to 24 hours primary rat
hepatocyte cultures.
[118]
Retroviral vector
SV40 Tag
Temperature-based regulation
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- Immortalized cells cultured at non-
permissive temperature (37°C):
■ Displayed morphologic
characteristics of
differentiated
hepatocytes.
■ Expressed increased
mRNA and protein levels
of ALB, ASGPR, and
androsterone-UGT.
■ Possessed markedly
decreased GST-Yp
expression.
- Transplantation into SCID mice
revealed no tumorigenic properties and
cells retained hepatocellular
morphology and G6P activity.
➢ Expression of ASGR was found to be
temperature-sensitive with higher
expression at 37°C compared to 39°C.
Consequently after SV40 Tag
degradation, cells were maintained at
37°C instead of 39°C.
Rat adult hepatocytes - Displayed morphology of primary
hepatocytes.
- Expressed ALB, G6P, DPP-IV, GGT
mRNA levels similar to normal
hepatocytes and ALB levels were
stable for at least a month.
- Secreted an amount of ALB equivalent
to primary hepatocytes, however once
transplanted in hepatectomized
nonalbumin rats, immortalized
hepatocytes did not generate
significantly elevated ALB levels
compared with primary hepatocytes.
- Were not tumorigenic.
[129, 147]
Human artificial mini chromosome
SV40 Tag
Recombinase- based control (FLP/FRT)
BQ1 BV1 WA1 WB6
Rat adult hepatocytes - Displayed typical epithelial cell
morphology.
- Cultured at non-permissive
temperature (37°C) expressed
decreased levels of p53.
- Although increased at non-permissive
temperature, production of ALB and
urea was still low compared to primary
hepatocytes and reached undetectable
levels with passage.
- Possessed increased telomerase
activity following immortalization but
no anchorage-independent cell growth
was visible.
- Distribution of chromosomes was
adapted during passaging. Significant
increase of tetraploid along with
passage (WA1/WB6/BQ1). For BV1
cells no significant change of
chromosome count with passage,
though several common chromosomal
aberrations, namely, trisomy,
[102]
Retroviral vector
SV40 Tag
Temperature-based regulation
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monosomy and unknown marker
chromosome noted only in higher
passages.
➢ It was demonstrated that conditionally
immortalized hepatocytes become
dedifferentiated by in vitro passage.
C8-B
Rat adult hepatocytes - Following Cre-recombinase treatment:
■ Regained morphological
characteristic of
differentiated
hepatocytes.
■ Showed increased mRNA
levels of ALB, HNF4 and
UGT1 and newly
detectable UGT2 and
ASGPR mRNA.
- Possessed no anchorage-independent
colony formation or tumor production.
➢ Ad-Cre infection was not 100%
efficient and some cells did not
undergo recombination.
[84]
Retroviral vector
SV40 Tag
Recombinase- based control (Cre-LoxP)
H2.35
Mice adult hepatocytes - Cultured at permissive temperature
exhibit extremely low ALB mRNA
levels.
- Cultured at non-permissive
temperature in serum-free medium and
collagen substratum possessed
dramatically increased ALB mRNA
levels.
[120]
Simian virus 40
SV40 Tag
Temperature-based regulation
L2A2
Rat adult hepatocytes - Cultured at non-permissive
temperature (37°C/39°C) regained the
morphological characteristics of
differentiated hepatocytes
- Possessed increased albumin
production at non-permissive
temperature
- Integrated normally into line cords and
appeared indistinguishable from native
liver parenchymal cells when
transplanted into normal rat liver.
- Once engrafted in the spleen of
portacaval-shunted rats, displayed
normal morphology, secreted bile,
expressed ALB mRNA and offered
protection from hyperammonemia-
induced hepatic encephalopathy.
- Were not tumorigenic.
[119, 179]
Retroviral vector
SV40 Tag
Temperature-based regulation
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Table 2
Overview of the available immortalization strategies
HSV-TK, herpes simplex virus thymidine kinase; hTERT, human telomerase reverse transcriptase; n.a., not
applicable; SV40 Tag, simian virus 40 large T antigen
Immortalizing genes
Rodent adult hepatocytes Human adult hepatocytes Human fetal hepatocytes
Viral oncogenes
- Allow the cells to
overcome the
proposed in vitro
telomere-
independent
growth arrest.
- Immortalization
of cells.
- Allow the cells to overcome
the proposed in vitro
telomere-independent
growth arrest.
- Expansion of in vitro
lifespan.
- Expansion of in vitro
lifespan.
hTERT n.a
- Contradicting results
available
- Does not allow the cells to
overcome the proposed in
vitro telomere-independent
growth arrest.
- Immortalization of cells.
Viral oncogenes
+ hTERT n.a
- Immortalization of cells.
- Immortalization of cells.
- Use of oncogenes may be
needed to overcome
premature growth arrest
which occurs when cells are
cultivated under
inappropriate culture
conditions [77, 108].
Conditional immortalization
Advantage Disadvantage
Temperature-based regulation
- Cell growth can easily be
manipulated by
temperature shift.
- SV40 Tag not active at
physiological temperature.
- The method is restricted to the temperature-
sensitive SV40 Tag mutant.
- The immortalization gene is not removed
from genome leading to potential risk for
tumorigenesis when used in vivo.
- Temperature shift can induce changes in
cellular properties and complicate
interpretation of study outcome.
Recombinase-based regulation
- Excision of immortalizing
gene upon Cre
recombinase expression
offers more possibilities
for in vivo applications.
- Associated with an irreversible growth
arrest.
- Proper reversion depends on efficient
transfer of recombinase gene.
- Risk for chromosomal rearrangement by
recombinase activity.
+ negative selection marker (HSV-
TK) Cells that underwent improper recombination can efficiently be eliminated by ganciclovir exposure.
+ tamoxifen-mediated self-excision Elevates the need of a secondary virus-mediated transfer of the recombinase gene.
Transcriptional regulation
- Allows switching between
the proliferating and
growth arrest state.
- Leaky transgene expression.
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Conditional immortalization
Advantage Disadvantage
- Expression of
immortalizing gene can be
controlled in vivo.
Gene transfer
Non-viral
Calcium phosphate precipitation
- High hepatocyte toxicity.
- Low gene transfer efficiencies.
Strontium phosphate transfection
- Low hepatocyte toxicity.
- Low gene transfer efficiencies.
Electroporation
- High hepatocyte toxicity.
- Low gene transfer efficiencies.
Lipid-mediated gene transfer
- When optimized, good gene transfer efficiencies can be obtained.
- Use of hepatocyte-specific ligands as transfection vehicle can lead to hepatocyte-specific
transfections.
Viral
Retroviral - Not able to transduce non-dividing cells.
Lentiviral
- Transduce both dividing and non-dividing cells.
- Transduction without affecting the differentiated phenotype.
- Improvement of lentiviral transduction efficiency by addition of growth factors and vitamin E
to the culture medium.
Human artificial chromosomes
- Lower transfer efficiency than viral vectors.
- Mitotically stable episomal maintenance.
- Allows incorporation of large genes under control of their regulatory elements.
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